🇺🇸 FDA

Company profile · Sponsor

Gilead

Gilead Sciences International Limited

E620DC8 · EMA pharma GB
Pipeline
24
Drugs
0
Patents
0

Quick answer

Gilead (E620DC8) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E620DC8
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (24)

Search pipeline →

  1. ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

    Gilead

    Primary Biliary Cholangitis

    phase 3 other active

    1 trial

  2. Abraxane 5 mg/ml powder for dispersion for infusion., Paclitaxel 6 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    Gilead

    PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting

    phase 3 small molecule active

    1 trial

  3. Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM ISL/LEN, ISLATRAVIR/LENACAPAVIR, ISLATRAVIR/LENACAPAVIR, PTM Biktarvy

    Gilead

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  4. Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  5. GS-1720, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-4182

    Gilead

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  6. GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720

    Gilead

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  7. GS-5245 tablets 175 mg, GS-5245 tablets 350 mg

    Gilead

    COVID-19

    phase 3 small molecule active

    1 trial

  8. Gemcitabine 38 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Gilead

    PD-L1 Positive Metastatic Triple-Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  9. HYCAMTIN 4 mg powder for concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  10. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Xeloda 500 mg film-coated tablets, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  11. LAMIVUDINE AND DOLUTEGRAVIR , DARUNAVIR , DORAVIRINE , DARUNAVIR AND COBICISTAT , EMTRICITABINE, TENOFOVIR ALAFENAMIDE, DARUNAVIR AND COBICISTAT, TENOFOVIR ALAFENAMIDE , RITONAVIR , ISLATRAVIR/LENACAPAVIR, LAMIVUDINE, ABACAVIR AND DOLUTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE, ELVITEGRAVIR AND COBICISTAT, EMTRICITABINE, RALTEGRAVIR , EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, EMTRICITABINE, TENOFOVIR DISOPROXIL AND RILPIVIRINE, DOLUTEGRAVIR , LAMIVUDINE, TENOFOVIR DISOPROXIL AND DORAVIRINE,

    Gilead

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  12. PACLITAXEL , Trodelvy 200 mg powder for concentrate for solution for infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion

    Gilead

    Recurrent or Persistent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  13. PTM 300 mg tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM 75/50 mg FDC tablets, PTM 50/200/25 mg FDC tablets, Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS

    Gilead

    HIV-1 infection

    phase 3 small molecule active

    1 trial

  14. Paclitaxel 6 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion

    Gilead

    Locally Advanced or Metastatic Unresectable Urothelial Cancer

    phase 3 small molecule active

    1 trial

  15. Placebo to match 10 mg, Placebo to match 5 mg

    Gilead

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  16. Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS

    Gilead

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  17. TENOFOVIR DISOPROXIL AND EMTRICITABINE , Sunlenca 300 mg film-coated tablets, Sunlenca 464 mg solution for injection

    Gilead

    Human Immunodeficiency Virus (HIV-1) infection

    phase 3 small molecule active

    1 trial

  18. Viread 245 mg film-coated tablets, Viread 123 mg film-coated tablets, Viread 204 mg film-coated tablets, PTM Tenofovir DF, Viread 163 mg film-coated tablets, Viread 33 mg/g granules

    Gilead

    Hepatitis B Infection

    phase 3 small molecule active

    1 trial

  19. Zimberelimab, CARBOPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, CISPLATIN , PACLITAXEL , Abraxane 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion

    Gilead

    Metastatic Non–Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, DOMVANALIMAB, Paclitaxel 6 mg/ml concentrate for solution for infusion, Zimberelimab

    Gilead

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  21. GS-4321 PLACEBO

    Gilead

    Chronic Hepatitis Delta.

    phase 2 small molecule active

    1 trial

  22. Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  23. PTM 75 mg Tablets, GS-1427, GS-1427, PTM 100 mg Tablets, GS-1427, PTM 25 mg Tablets

    Gilead

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  24. Pemetrexed Ribosepharm 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatine Hikma 450 mg/45 ml Infusionslösung, Pemetrexed Hexal 25 mg/ml infuusiokonsentraatti, liuosta varten, Cisplatine 1 mg/ml PCH, concentraat voor oplossing voor infusie, Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, DOMVANALIMAB, Pemetrexed NeoCorp 25 mg/ml Konzentrat zur Herstellung einer Infusionslös

    Gilead

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Gilead?

Gilead (E620DC8) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Gilead sponsor?

We track 24 ClinicalTrials.gov-linked programs for Gilead, including ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Gilead company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.